Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Pharmacological and Toxicological Methods|January 19, 2016
PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology dataLinnéa Bergenholm, Teresa Collins, Neil D Evans, et al.
The Journal of Biological Chemistry|February 13, 2013
Insulin signaling in type 2 diabetes: experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytesCecilia Brännmark, Elin Nyman, Siri Fagerholm, et al.
Frontiers in Physiology|December 21, 2016
Parameter Identifiability of Fundamental Pharmacodynamic ModelsDavid L I Janzén, Linnéa Bergenholm, Mats Jirstrand, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 26, 2023
A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohortsJane Knöchel, Linnéa Bergenholm, Eman Ibrahim, et al.
Frontiers in Pharmacology|September 6, 2021
Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid BiomarkersElsbet J Pieterman, Hans M G Princen, Annica Jarke, et al.
Scandinavian Journal of Gastroenterology|June 3, 2026
Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver diseaseSara F Hansson, Patrik Nasr, Jane Knöchel, et al.
Hepatology Communications|July 14, 2022
Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humansElke Ericson, Linnéa Bergenholm, Anne-Christine Andréasson, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 5, 2021
Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogsV Sashi Gopaul, Elsbet J Pieterman, Hans M G Princen, et al.
Journal of Hepatology|January 11, 2025
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trialsJavier Armisen, Mitra Rauschecker, Janeli Sarv, et al.
Circulation|May 15, 2026
Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive PatientsRick B Vega, Gavin O'Mahony, April M Barbour, et al.
Pageof 1